Physician profile
Roger E Kelley
NPI 1114943990
$2,721.28
in general payments reported to CMS, 2019-2025
21 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $120 · 2021: $540 · 2022: $617 · 2023: $239 · 2024: $323 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.63 | 2021-2025 | |
| Horizon Therapeutics Plc | $405.24 | 2022-2023 | Uplizna |
| Genzyme Corporation | $302.14 | 2019-2022 | |
| Pfizer INC. | $290.66 | 2023-2025 | |
| Ucb, INC. | $180.89 | 2023-2025 | Fintepla, Rystiggo |
| Livanova USA, INC. | $146.06 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $137.07 | 2019-2025 | Kisunla |
| Biogen, INC. | $130.93 | 2019-2022 | |
| Amgen INC. | $115.42 | 2019-2025 | Uplizna |
| Allergan, INC. | $74.88 | 2019-2021 | |
| Mdd US Operations, LLC | $62.81 | 2024 | Gocovri |
| Amneal Pharmaceuticals LLC | $52.20 | 2024-2025 | Rytary, Crexont |
| Biohaven Pharmaceuticals, INC. | $38.22 | 2021 | |
| Acadia Pharmaceuticals INC | $35.10 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $27.29 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.32 | 2025 | |
| Ani Pharmaceuticals, INC. | $15.78 | 2024 | Purified Cortrophin Gel |
| Ge Healthcare | $14.26 | 2021 | |
| Revance Therapeutics, INC. | $13.50 | 2024 | Daxxify |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.